Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginesatide for antibody-mediated pure red cell aplasia in chronic kidney disease
2005-004944-30Phase 2Completed
- Sponsor
- Takeda
- Start
- Dec 2005
- Modality
- Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of peginesatide in anaemia, pure red cell aplasia (PRCA) and chronic kidney disease (CKD), sponsored by Takeda. Primary endpoint: Hemoglobin response by week 24. Started Dec 2005; status: completed.
02
Drugs
peginesatide
03
Conditions
anaemiapure red cell aplasia (PRCA)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2005-004944-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004944-30.